Jump to content

Icosagen (company)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DeprecatedFixerBot (talk | contribs) at 01:37, 15 May 2018 (Removed deprecated parameter(s) from Template:Div col using DeprecatedFixerBot. Questions? See Template:Div col#Usage of "cols" parameter or msg TSD! (please mention that this is task #2!))). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Icosagen AS
Company typePrivately held company
IndustryBiotechnology, Biopharmaceutical industry
Founded1999
HeadquartersTartu, Estonia
Key people
Mart Ustav (Founder and CEO)
ProductsProducts and services in functional genomics and proteomics, latex allergen tests
ServicesCertification: ISO 9001:2000
Websiteicosagen.com

Icosagen is a biotechnology company in Estonia[1] providing medical diagnostics services and performing custom research programs for the biopharmaceutical industry. As of March 2009, Quattromed has been renamed Icosagen AS.

Profile

Quattromed was established in 1999 as a spin-off from Tartu University.[2] It is based in Tartu, Estonia. Employing 80 full-time employees, it has grown into the largest biotechnology company in Estonia.[citation needed] Quattromed started with offering molecular diagnostic services, and today the company covers molecular and clinical diagnostic (Quattromed HTI Laboratories), life science products (Quattromed), latex allergen testing (Quattromed Ltd) and protein production (Quattromed Cell Factory).

Products and services

Icosagen’s activities are divided into three branches: medical diagnostics division, technology development division, and life science products division. Its main focus is in gene expression and protein production. In-house proprietary technologies are used combined with extensive process know-how and partnership with academic and industrial groups. Quattromed has three patent applications in its IP portfolio, about ten technology licenses and one trademark.

Icosagen’s main products are:

See also

References

  1. ^ Frank L. (2001). "Biotechnology in the Baltic". Nature Biotechnology. 19 (6): 513–5. doi:10.1038/89229. PMID 11385442.
  2. ^ Estonian Biotechnology Association Archived October 21, 2007, at the Wayback Machine. Retrieved 18. June 2007.
  3. ^ Kurg R; Parik J; Juronen E; Sedman T; Abroi A; Liiv I; Langel U; Ustav M. (1999). "Effect of bovine papillomavirus E2 protein-specific monoclonal antibodies on papillomavirus DNA replication". Journal of Virology. 73 (6): 4670–7. PMC 112508. PMID 10233926.
  4. ^ Kaldalu N; Lepik D; Kristjuhan A; Ustav M. (2000). "Monitoring and purification of proteins using bovine papillomavirus E2 epitope tags". Biotechniques. 28 (3): 456–60. PMID 10723557.